SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOHN W. who wrote (3380)12/19/1997 2:47:00 PM
From: margie  Read Replies (2) of 6136
 
Agouron expects a series of new clinical data -at least 20 abstracts according to Agouron, to be presented at the annual Retrovirus meeting in Chicago in February, including more on the Viracept BID regimen; combinations of Viracept with other Protease inhibitors -including Crixivan; Fortovase- saq-sgc; 141-W94; Norvir; also with DMP 266.

Future BID dosing regimen: Preliminary data from a Viracept BID dosing study demonstrated as good if not better response rates than that achieved with a Crixivan BID dosing study (100% response rate at 16 weeks versus in 9/9 patients on Viracept vs 75% response rate at 20 weeks for Crixivan (12/16 patients).
Expecting preliminary data from a larger Agouron study with 300 patients to be presented in early 1998.

Viracept approval is expected in Europe and Canada by calender Q1 98, with market approval in Japan also expected in 1998

Hit Hard, Hit Early- Expects earlier and more aggressive reatment to fuel growth in the patient population among both symptomatic and asymptomatic patients at earlier stages of disease.
Now NIH/DHHS and IAS guidelines:
Present indications are for triple combo therapy when
when CD4 + 10,000
Discussions are ongoing as to whether this viral load threshold should be lowered to <5000 copies
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News